Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Rises By 48.8%

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 142,800 shares, an increase of 48.8% from the February 28th total of 96,000 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily volume of 222,800 shares, the short-interest ratio is currently 0.6 days.

Entero Therapeutics Stock Performance

Shares of NASDAQ:ENTO traded up $0.03 on Monday, hitting $0.51. 23,517 shares of the company were exchanged, compared to its average volume of 380,401. The company’s 50 day moving average price is $0.52 and its two-hundred day moving average price is $0.53. Entero Therapeutics has a one year low of $0.19 and a one year high of $3.16.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.